ArticleEndocrine-related cancer2026
Adrenocortical carcinoma as a manifestation of Birt-Hogg-Dubé syndrome.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Birt-Hogg-Dubé syndrome (BHDS) is characterized by fibrofolliculomas, trichodiscomas, renal tumors, lung cysts, and spontaneous pneumothoraces. Other than renal cell carcinoma, no cancers have been confirmed as part of the BHDS tumor spectrum. Here, we set out to uncover if adrenocortical carcinoma (ACC) is associated with BHDS. A retrospective review at a single tertiary care center between 2010 and 2024 was performed using search terms describing the clinical manifestations of BHDS, adrenal tumors, and iterations thereof. The initial review identified 1,010 patients with ACC. Of these patients, 466 were evaluated by a genetic counselor, and 346 underwent genetic testing-seven of which were found to have either characteristic clinical features of BHDS or a confirmed diagnosis. The literature review over the same time period demonstrated five additional cases of malignant adrenal tumors in patients with BHDS. We observed BHDS, confirmed by a pathogenic FLCN variant in 0.7% of all ACC patients, or 1.5% of patients evaluated by a genetic counselor and 2.0% of all patients who underwent genetic testing. Testing for FLCN pathogenic variants should be considered during routine genetic evaluation of patients with ACC, and special attention should be paid to adrenal tumors in BHDS patients during surveillance for renal neoplasms as more than 50% of patients in this series developed metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.